Alzheimer's disease: Pathological mechanisms and recent insights

Current Neuropharmacology

Volumn 9, Issue 4, 2011, Pages 674-684

  Niedowicz, Dana M ^a   Nelson, Peter T ^a,b   Paul Murphy, M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Amyloid; Amyloid peptide; Amyloid precursor protein; Neurodegeneration; Protein misfolding; Proteinopathies; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CELECOXIB; HOMOTAURINE; HYPOCHOLESTEROLEMIC AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; TARENFLURBIL;

ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; DRUG COST; FRONTOTEMPORAL DEMENTIA; HUMAN; NONHUMAN; PATHOGENESIS;

EID: 82955220477     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911798376181     Document Type: Article

References (111)

1. He, W.; Sengupta, M.; Velkoff, V.A.; DeBarros, K.A. 65+ in the United States. In: Commerce, U.S.D.o., Ed.; U.S. Government Printing Office: Washington, D.C.; 2005, pp. 254.
2. Ferri, C.P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P.R.; Rimmer, E.; Scazufca, M. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366(9503), 2112-2117.
3. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
4. Glenner, G.G.; Wong, C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun., 1984, 122, 1131-1135.
5. Masters, C.L.; Multhaup, G.; Simms, G.; Pottgiesser, J.; Martins, R.N.; Beyreuther, K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J., 1985, 4, 2757-2763.
6. Masters, C.L.; Simms, G.; Weinman, N.A.; Multhaup, G.; McDonald, B.L.; Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A., 1985, 82, 4245-4249.
7. Querfurth, H.W.; LaFerla, F.M. Alzheimer's disease. N. Engl. J. Med., 2010, 362(4), 329-344.
8. Nelson, P.T.; Jicha, G.A.; Schmitt, F.A.; Liu, H.; Davis, D.G.; Mendiondo, M.S.; Abner, E.L.; Markesbery, W.R. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J. Neuropathol. Exp. Neurol., 2007, 66(12), 1136-1146.
9. NIA. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol. Aging, 1997, 18(4 Suppl), S1-2.
10. Ludolph, A.C.; Kassubek, J.; Landwehrmeyer, B.G.; Mandelkow, E.; Mandelkow, E.M.; Burn, D.J.; Caparros-Lefebvre, D.; Frey, K.A.; de Yebenes, J.G.; Gasser, T.; Heutink, P.; Hoglinger, G.; Jamrozik, Z.; Jellinger, K.A.; Kazantsev, A.; Kretzschmar, H.; Lang, A.E.; Litvan, I.; Lucas, J.J.; McGeer, P.L.; Melquist, S.; Oertel, W.; Otto, M.; Paviour, D.; Reum, T.; Saint-Raymond, A.; Steele, J.C.; Tolnay, M.; Tumani, H.; van Swieten, J.C.; Vanier, M.T.; Vonsattel, J.P.; Wagner, S.; Wszolek, Z.K. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur. J. Neurol., 2009, 16(3), 297 309.
11. Liberski, P.P. Amyloid plaques in transmissible spongiform encephalopathies (prion diseases). Folia Neuropathol., 2004, 42 Suppl B, 109-119.
12. Dickson, D.W.; Braak, H.; Duda, J.E.; Duyckaerts, C.; Gasser, T.; Halliday, G.M.; Hardy, J.; Leverenz, J.B.; Del Tredici, K.; Wszolek, Z.K.; Litvan, I. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol., 2009, 8(12), 1150-1157.
13. Jellinger, K.A. Formation and development of Lewy pathology: a critical update. J. Neurol., 2009, 256 Suppl 3, 270-279.
14. Shulman, J.M.; De Jager, P.L. Evidence for a common pathway linking neurodegenerative diseases. Nat. Genet., 2009, 41(12), 1261-1262.
15. Vassar, R.; Bennett, B.D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E.A.; Denis, P.; Teplow, D.B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M.A.; Biere, A.L.; Curran, E.; Burgess, T.; Louis, J.C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 1999, 286(5440), 735-741.
16. Cao, X.; Sudhof, T.C. A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science, 2001, 293(5527), 115-120.
17. Gao, Y.; Pimplikar, S.W. The gamma-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc. Natl. Acad. Sci. U. S.A., 2001, 98(26), 14979-14984.
18. Kimberly, W.T.; Zheng, J.B.; Guenette, S.Y.; Selkoe, D.J. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J. Biol. Chem., 2001, 276(43), 40288-40292.
19. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81(2), 741-766.
20. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300(5618), 486-489.
21. Walsh, D.M.; Selkoe, D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron, 2004, 44(1), 181 193.
22. De Strooper, B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep., 2007, 8(2), 141-146.
23. Wolfe, M.S. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep., 2007, 8(2), 136-140.
24. Hardy, J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem., 2009, 110(4), 1129-1134.
25. Gatz, M.; Reynolds, C.A.; Fratiglioni, L.; Johansson, B.; Mortimer, J.A.; Berg, S.; Fiske, A.; Pedersen, N.L. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry, 2006, 63(2), 168-174.
26. Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W.; Roses, A.D.; Haines, J.L.; Pericak Vance, M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993, 261, 921-923.
27. Kim, J.; Basak, J.M.; Holtzman, D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron, 2009, 63(3), 287-303.
28. Roses, A.D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med., 1996, 47, 387-400.
29. Sleegers, K.; Lambert, J.C.; Bertram, L.; Cruts, M.; Amouyel, P.; Van Broeckhoven, C. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet., 2010, 26(2), 84-93.
30. Harold, D.; Abraham, R.; Hollingworth, P.; Sims, R.; Gerrish, A.; Hamshere, M.L.; Pahwa, J.S.; Moskvina, V.; Dowzell, K.; Williams, A.; Jones, N.; Thomas, C.; Stretton, A.; Morgan, A.R.; Lovestone, S.; Powell, J.; Proitsi, P.; Lupton, M.K.; Brayne, C.; Rubinsztein, D.C.; Gill, M.; Lawlor, B.; Lynch, A.; Morgan, K.; Brown, K.S.; Passmore, P.A.; Craig, D.; McGuinness, B.; Todd, S.; Holmes, C.; Mann, D.; Smith, A.D.; Love, S.; Kehoe, P.G.; Hardy, J.; Mead, S.; Fox, N.; Rossor, M.; Collinge, J.; Maier, W.; Jessen, F.; Schurmann, B.; van den Bussche, H.; Heuser, I.; Kornhuber, J.; Wiltfang, J.; Dichgans, M.; Frolich, L.; Hampel, H.; Hull, M.; Rujescu, D.; Goate, A.M.; Kauwe, J.S.; Cruchaga, C.; Nowotny, P.; Morris, J.C.; Mayo, K.; Sleegers, K.; Bettens, K.; Engelborghs, S.; De Deyn, P.P.; Van Broeckhoven, C.; Livingston, G.; Bass, N.J.; Gurling, H.; McQuillin, A.; Gwilliam, R.; Deloukas, P.; Al Chalabi, A.; Shaw, C.E.; Tsolaki, M.; Singleton, A.B.; Guerreiro, R.; Muhleisen, T.W.; Nothen, M.M.; Moebus, S.; Jockel, K.H.; Klopp, N.; Wichmann, H.E.; Carrasquillo, M.M.; Pankratz, V.S.; Younkin, S.G.; Holmans, P.A.; O'Donovan, M.; Owen, M.J.; Williams, J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet., 2009, 41(10), 1088-1093.
31. Lambert, J.C.; Heath, S.; Even, G.; Campion, D.; Sleegers, K.; Hiltunen, M.; Combarros, O.; Zelenika, D.; Bullido, M.J.; Tavernier, B.; Letenneur, L.; Bettens, K.; Berr, C.; Pasquier, F.; Fievet, N.; Barberger-Gateau, P.; Engelborghs, S.; De Deyn, P.; Mateo, I.; Franck, A.; Helisalmi, S.; Porcellini, E.; Hanon, O.; de Pancorbo, M.M.; Lendon, C.; Dufouil, C.; Jaillard, C.; Leveillard, T.; Alvarez, V.; Bosco, P.; Mancuso, M.; Panza, F.; Nacmias, B.; Bossu, P.; Piccardi, P.; Annoni, G.; Seripa, D.; Galimberti, D.; Hannequin, D.; Licastro, F.; Soininen, H.; Ritchie, K.; Blanche, H.; Dartigues, J.F.; Tzourio, C.; Gut, I.; Van Broeckhoven, C.; Alperovitch, A.; Lathrop, M.; Amouyel, P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet., 2009, 41(10), 1094-1099.
32. Lindsay, J.; Laurin, D.; Verreault, R.; Hebert, R.; Helliwell, B.; Hill, G.B.; McDowell, I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol., 2002, 156(5), 445-453.
33. Bishop, N.A.; Lu, T.; Yankner, B.A. Neural mechanisms of ageing and cognitive decline. Nature, 2010, 464(7288), 529-535.
34. Wolozin, B.; Wang, S.W.; Li, N.C.; Lee, A.; Lee, T.A.; Kazis, L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med., 2007, 5, 20.
35. McGeer, P.L.; McGeer, E.G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging, 2007, 28(5), 639-647.
36. Luchsinger, J.A.; Gustafson, D.R. Adiposity, type 2 diabetes, and Alzheimer's disease. J. Alzheimers Dis., 2009, 16(4), 693-704.
37. Nelson, P.T.; Smith, C.D.; Abner, E.A.; Schmitt, F.A.; Scheff, S.W.; Davis, G.J.; Keller, J.N.; Jicha, G.A.; Davis, D.; Wang-Xia, W.; Hartman, A.; Katz, D.G.; Markesbery, W.R. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim. Biophys. Acta, 2009, 1792(5), 454-469.
38. Munzberg, H.; Bjornholm, M.; Bates, S.H.; Myers, M.G., Jr. Leptin receptor action and mechanisms of leptin resistance. Cell Mol. Life Sci., 2005, 62(6), 642-652.
39. Tezapsidis, N.; Johnston, J.M.; Smith, M.A.; Ashford, J.W.; Casadesus, G.; Robakis, N.K.; Wolozin, B.; Perry, G.; Zhu, X.; Greco, S.J.; Sarkar, S. Leptin: a novel therapeutic strategy for Alzheimer's disease. J. Alzheimers Dis., 2009, 16(4), 731-740.
40. Lieb, W.; Beiser, A.S.; Vasan, R.S.; Tan, Z.S.; Au, R.; Harris, T.B.; Roubenoff, R.; Auerbach, S.; DeCarli, C.; Wolf, P.A.; Seshadri, S. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA, 2009, 302(23), 2565 2572.
41. Whitmer, R.A.; Gunderson, E.P.; Barrett-Connor, E.; Quesenberry, C.P., Jr.; Yaffe, K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ, 2005, 330(7504), 1360.
42. Iwata, N.; Tsubuki, S.; Takaki, Y.; Watanabe, K.; Sekiguchi, M.; Hosoki, E.; Kawashima-Morishima, M.; Lee, H.J.; Hama, E.; Sekine-Aizawa, Y.; Saido, T.C. Identification of the major Abeta1 42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med., 2000, 6(2), 143-150.
43. Iwata, N.; Tsubuki, S.; Takaki, Y.; Shirotani, K.; Lu, B.; Gerard, N.P.; Gerard, C.; Hama, E.; Lee, H.J.; Saido, T.C. Metabolic regulation of brain Abeta by neprilysin. Science, 2001, 292(5521), 1550-1552.
44. Marr, R.A.; Rockenstein, E.; Mukherjee, A.; Kindy, M.S.; Hersh, L.B.; Gage, F.H.; Verma, I.M.; Masliah, E. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci., 2003, 23(6), 1992-1996.
45. Miller, B.C.; Eckman, E.A.; Sambamurti, K.; Dobbs, N.; Chow, K.M.; Eckman, C.B.; Hersh, L.B.; Thiele, D.L. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(10), 6221-6226.
46. Huang, S.M.; Mouri, A.; Kokubo, H.; Nakajima, R.; Suemoto, T.; Higuchi, M.; Staufenbiel, M.; Noda, Y.; Yamaguchi, H.; Nabeshima, T.; Saido, T.C.; Iwata, N. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem., 2006, 281(26), 17941-17951.
47. Caccamo, A.; Oddo, S.; Sugarman, M.C.; Akbari, Y.; LaFerla, F.M. Age and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol. Aging, 2005, 26(5), 645-654.
48. Miners, J.S.; Van Helmond, Z.; Chalmers, K.; Wilcock, G.; Love, S.; Kehoe, P.G. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol., 2006, 65(10), 1012-1021.
49. Maruyama, M.; Higuchi, M.; Takaki, Y.; Matsuba, Y.; Tanji, H.; Nemoto, M.; Tomita, N.; Matsui, T.; Iwata, N.; Mizukami, H.; Muramatsu, S.; Ozawa, K.; Saido, T.C.; Arai, H.; Sasaki, H. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann. Neurol., 2005, 57(6), 832-842.
50. Shibata, M.; Yamada, S.; Kumar, S.R.; Calero, M.; Bading, J.; Frangione, B.; Holtzman, D.M.; Miller, C.A.; Strickland, D.K.; Ghiso, J.; Zlokovic, B.V. Clearance of Alzheimer's amyloid-ss(1 40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest., 2000, 106(12), 1489-1499.
51. Deane, R.; Du Yan, S.; Submamaryan, R.K.; LaRue, B.; Jovanovic, S.; Hogg, E.; Welch, D.; Manness, L.; Lin, C.; Yu, J.; Zhu, H.; Ghiso, J.; Frangione, B.; Stern, A.; Schmidt, A.M.; Armstrong, D.L.; Arnold, B.; Liliensiek, B.; Nawroth, P.; Hofman, F.; Kindy, M.; Stern, D.; Zlokovic, B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med., 2003, 9(7), 907-913.
52. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Paul, S.M.; Holtzman, D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science, 2002, 295(5563), 2264-2267.
53. Van Uden, E.; Mallory, M.; Veinbergs, I.; Alford, M.; Rockenstein, E.; Masliah, E. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J. Neurosci., 2002, 22(21), 9298-9304.
54. Zlokovic, B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci, 2005, 28(4), 202-208.
55. Deshpande, A.; Mina, E.; Glabe, C.; Busciglio, J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci., 2006, 26(22), 6011-6018.
56. Georganopoulou, D.G.; Chang, L.; Nam, J.M.; Thaxton, C.S.; Mufson, E.J.; Klein, W.L.; Mirkin, C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(7), 2273-2276.
57. Koffie, R.M.; Meyer-Luehmann, M.; Hashimoto, T.; Adams, K.W.; Mielke, M.L.; Garcia-Alloza, M.; Micheva, K.D.; Smith, S.J.; Kim, M.L.; Lee, V.M.; Hyman, B.T.; Spires-Jones, T.L. Oligomeric amyloid {beta} associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U. S. A., 2009, 106(10), 4012-7.
58. Bitan, G.; Kirkitadze, M.D.; Lomakin, A.; Vollers, S.S.; Benedek, G.B.; Teplow, D.B. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(1), 330-335.
59. Duering, M.; Grimm, M.O.; Grimm, H.S.; Schroder, J.; Hartmann, T. Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiol. Aging, 2005, 26(6), 785-788.
60. McGowan, E.; Pickford, F.; Kim, J.; Onstead, L.; Eriksen, J.; Yu, C.; Skipper, L.; Murphy, M.P.; Beard, J.; Das, P.; Jansen, K.; Delucia, M.; Lin, W.L.; Dolios, G.; Wang, R.; Eckman, C.B.; Dickson, D.W.; Hutton, M.; Hardy, J.; Golde, T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron, 2005, 47(2), 191-199.
61. Walsh, D.M.; Klyubin, I.; Fadeeva, J.V.; Cullen, W.K.; Anwyl, R.; Wolfe, M.S.; Rowan, M.J.; Selkoe, D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 2002, 416(6880), 535-539.
62. Klyubin, I.; Betts, V.; Welzel, A.T.; Blennow, K.; Zetterberg, H.; Wallin, A.; Lemere, C.A.; Cullen, W.K.; Peng, Y.; Wisniewski, T.; Selkoe, D.J.; Anwyl, R.; Walsh, D.M.; Rowan, M.J. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci., 2008, 28(16), 4231-4237.
63. Shankar, G.M.; Li, S.; Mehta, T.H.; Garcia-Munoz, A.; Shepardson, N.E.; Smith, I.; Brett, F.M.; Farrell, M.A.; Rowan, M.J.; Lemere, C.A.; Regan, C.M.; Walsh, D.M.; Sabatini, B.L.; Selkoe, D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med., 2008, 14(8), 837-842.
64. Kayed, R.; Sokolov, Y.; Edmonds, B.; McIntire, T.M.; Milton, S.C.; Hall, J.E.; Glabe, C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem., 2004, 279(45), 46363-46366.
65. Sokolov, Y.; Kozak, J.A.; Kayed, R.; Chanturiya, A.; Glabe, C.; Hall, J.E. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J. Gen. Physiol., 2006, 128(6), 637 647.
66. Gamblin, T.C.; Chen, F.; Zambrano, A.; Abraha, A.; Lagalwar, S.; Guillozet, A.L.; Lu, M.; Fu, Y.; Garcia-Sierra, F.; LaPointe, N.; Miller, R.; Berry, R.W.; Binder, L.I.; Cryns, V.L. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(17), 10032 10037.
67. Kawabata, S.; Higgins, G.A.; Gordon, J.W. Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein [retracted by Kawabata S, Higgins GA, Gordon JW. In: Nature 1992 Mar 5;356(6364):23 and Nature 1992 Mar 19;356(6366):265] [see comments]. Nature, 1991, 354(6353), 476 478.
68. Mackenzie, I.R.; Neumann, M.; Bigio, E.H.; Cairns, N.J.; Alafuzoff, I.; Kril, J.; Kovacs, G.G.; Ghetti, B.; Halliday, G.; Holm, I.E.; Ince, P.G.; Kamphorst, W.; Revesz, T.; Rozemuller, A.J.; Kumar-Singh, S.; Akiyama, H.; Baborie, A.; Spina, S.; Dickson, D.W.; Trojanowski, J.Q.; Mann, D.M. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol., 2010, 119(1), 1-4.
69. Hutton, M.; Lendon, C.L.; Rizzu, P.; Baker, M.; Froelich, S.; Houlden, H.; Pickering-Brown, S.; Chakraverty, S.; Isaacs, A.; Grover, A.; Hackett, J.; Adamson, J.; Lincoln, S.; Dickson, D.; Davies, P.; Petersen, R.C.; Stevens, M.; de Graaff, E.; Wauters, E.; van Baren, J.; Hillebrand, M.; Joosse, M.; Kwon, J.M.; Nowotny, P.; Che, L.K.; Norton, J.; Morris, J.C.; Reed, L.A.; Trojanowski, J.; Basun, H.; Lannfelt, L.; Neystat, M.; Fahn, S.; Dark, F.; Tannenberg, T.; Dodd, P.R.; Hayward, N.; Kwok, J.B.; Schofield, P.R.; Andreadis, A.; Snowden, J.; Craufurd, D.; Neary, D.; Owen, F.; Oostra, B.A.; Hardy, J.; Goate, A.; van Swieten, J.; Mann, D.; Lynch, T.; Heutink, P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 1998, 393(6686), 702-705.
70. Spillantini, M.G.; Murrell, J.R.; Goedert, M.; Farlow, M.R.; Klug, A.; Ghetti, B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(13), 7737-7741.
71. Games, D.; Buttini, M.; Kobayashi, D.; Schenk, D.; Seubert, P. Mice as models: transgenic approaches and Alzheimer's disease. J. Alzheimers Dis., 2006, 9(3 Suppl), 133-149.
72. McGowan, E.; Eriksen, J.; Hutton, M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet., 2006, 22(5), 281-289.
73. LeVine, H.; Walker, L.C. Model's of Alzheimer's Disease. In: Handbook of Models for Human Aging, Conn, M.P., Ed.; Academic Press / Elsevier: New York; 2006, pp. 121-134.
74. Oakley, H.; Cole, S.L.; Logan, S.; Maus, E.; Shao, P.; Craft, J.; Guillozet-Bongaarts, A.; Ohno, M.; Disterhoft, J.; Van Eldik, L.; Berry, R.; Vassar, R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci., 2006, 26(40), 10129-10140.
75. Flood, D.G.; Reaume, A.G.; Dorfman, K.S.; Lin, Y.G.; Lang, D.M.; Trusko, S.P.; Savage, M.J.; Annaert, W.G.; De Strooper, B.; Siman, R.; Scott, R.W. FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol. Aging, 2002, 23(3), 335-348.
76. Murphy, M.P.; Beckett, T.L.; Ding, Q.; Patel, E.; Markesbery, W.R.; St Clair, D.K.; LeVine, H., 3rd; Keller, J.N. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol. Dis., 2007, 27(3), 301-311.
77. Fung, J.; Frost, D.; Chakrabartty, A.; McLaurin, J. Interaction of human and mouse Abeta peptides. J. Neurochem., 2004, 91(6), 1398-1403.
78. Jankowsky, J.L.; Younkin, L.H.; Gonzales, V.; Fadale, D.J.; Slunt, H.H.; Lester, H.A.; Younkin, S.G.; Borchelt, D.R. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J. Biol. Chem., 2007, 282(31), 22707-22720.
79. Ye, L.; Morgenstern, J.L.; Lamb, J.R.; Lockhart, A. Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers. Biochem. Biophys. Res. Commun., 2006, 347(3), 669-677.
80. Gotz, J.; Chen, F.; van Dorpe, J.; Nitsch, R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science, 2001, 293(5534), 1491-1495.
81. Lewis, J.; Dickson, D.W.; Lin, W.L.; Chisholm, L.; Corral, A.; Jones, G.; Yen, S.H.; Sahara, N.; Skipper, L.; Yager, D.; Eckman, C.; Hardy, J.; Hutton, M.; McGowan, E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 2001, 293(5534), 1487-1491.
82. Meyer-Luehmann, M.; Spires-Jones, T.L.; Prada, C.; Garcia Alloza, M.; de Calignon, A.; Rozkalne, A.; Koenigsknecht-Talboo, J.; Holtzman, D.M.; Bacskai, B.J.; Hyman, B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature, 2008, 451(7179), 720-724.
83. Philipson, O.; Lord, A.; Gumucio, A.; O'Callaghan, P.; Lannfelt, L.; Nilsson, L.N. Animal models of amyloid-beta-related pathologies in Alzheimer's disease. FEBS J., 2010, 277(6), 1389 1409.
84. Woodruff-Pak, D.S. Animal models of Alzheimer's disease: therapeutic implications. J. Alzheimers Dis., 2008, 15(4), 507-521.
85. Elder, G.A.; Gama Sosa, M.A.; De Gasperi, R. Transgenic mouse models of Alzheimer's disease. Mt Sinai J. Med., 2010, 77(1), 69-81.
86. Kalback, W.; Watson, M.D.; Kokjohn, T.A.; Kuo, Y.M.; Weiss, N.; Luehrs, D.C.; Lopez, J.; Brune, D.; Sisodia, S.S.; Staufenbiel, M.; Emmerling, M.; Roher, A.E. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry, 2002, 41(3), 922-928.
87. Clavaguera, F.; Bolmont, T.; Crowther, R.A.; Abramowski, D.; Frank, S.; Probst, A.; Fraser, G.; Stalder, A.K.; Beibel, M.; Staufenbiel, M.; Jucker, M.; Goedert, M.; Tolnay, M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol., 2009, 11(7), 909-913.
88. Frost, B.; Jacks, R.L.; Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem., 2009, 284(19), 12845-12852.
89. Green, R.C.; Schneider, L.S.; Amato, D.A.; Beelen, A.P.; Wilcock, G.; Swabb, E.A.; Zavitz, K.H. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA, 2009, 302(23), 2557-2564.
90. Gauthier, S.; Aisen, P.S.; Ferris, S.H.; Saumier, D.; Duong, A.; Haine, D.; Garceau, D.; Suhy, J.; Oh, J.; Lau, W.; Sampalis, J. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J. Nutr. Health Aging, 2009, 13(6), 550-557.
91. Aristide, V.; Hamm, R. Results from Largest Statin Study of Patients with Alzheimer's Disease Show Lipitor Has No Significant Impact on Disease. In; Thomson Reuters; 2008.
92. Martin, B.K.; Szekely, C.; Brandt, J.; Piantadosi, S.; Breitner, J.C.; Craft, S.; Evans, D.; Green, R.; Mullan, M. Cognitive Function Over Time in the Alzheimer's Disease Antiinflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib. Arch. Neurol., 2008, 65(7), 896-905.
93. Shumaker, S.A.; Legault, C.; Rapp, S.R.; Thal, L.; Wallace, R.B.; Ockene, J.K.; Hendrix, S.L.; Jones, B.N., 3rd; Assaf, A.R.; Jackson, R.D.; Kotchen, J.M.; Wassertheil-Smoller, S.; Wactawski Wende, J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA, 2003, 289(20), 2651-2662.
94. Sparks, D.L.; Connor, D.J.; Sabbagh, M.N.; Petersen, R.B.; Lopez, J.; Browne, P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol. Scand. Suppl, 2006, 185, 3-7.
95. Aisen, P.S.; Gauthier, S.; Vellas, B.; Briand, R.; Saumier, D.; Laurin, J.; Garceau, D. Alzhemed: a potential treatment for Alzheimer's disease. Curr. Alzheimer Res., 2007, 4(4), 473-478.
96. Wilcock, G.K.; Black, S.E.; Hendrix, S.B.; Zavitz, K.H.; Swabb, E.A.; Laughlin, M.A. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol., 2008, 7(6), 483-493.
97. Brody, D.L.; Holtzman, D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci., 2008, 31, 175-193.
98. Das, P.; Murphy, M.P.; Younkin, L.H.; Younkin, S.G.; Golde, T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging, 2001, 22(5), 721-727.
99. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408(6815), 982-985.
100. Head, E.; Pop, V.; Vasilevko, V.; Hill, M.; Saing, T.; Sarsoza, F.; Nistor, M.; Christie, L.A.; Milton, S.; Glabe, C.; Barrett, E.; Cribbs, D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J. Neurosci., 2008, 28(14), 3555-3566.
101. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372(9634), 216-223.
102. Markesbery, W.R.; Schmitt, F.A.; Kryscio, R.J.; Davis, D.G.; Smith, C.D.; Wekstein, D.R. Neuropathologic substrate of mild cognitive impairment. Arch. Neurol., 2006, 63(1), 38-46.
103. Cummings, J.L.; Doody, R.; Clark, C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology, 2007, 69(16), 1622-1634.
104. Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease. Cell, 2008, 132(1), 27-42.
105. Harrison, D.E.; Strong, R.; Sharp, Z.D.; Nelson, J.F.; Astle, C.M.; Flurkey, K.; Nadon, N.L.; Wilkinson, J.E.; Frenkel, K.; Carter, C.S.; Pahor, M.; Javors, M.A.; Fernandez, E.; Miller, R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 2009, 460(7253), 392-395.
106. Caccamo, A.; Majumder, S.; Richardson, A.; Strong, R.; Oddo, S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem., 2010, 285(17), 13107-13120.
107. Renna, M.; Jimenez-Sanchez, M.; Sarkar, S.; Rubinsztein, D.C. Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J. Biol. Chem., 2010, 285(15), 11061-11067.
108. Sonnen, J.A.; Larson, E.B.; Crane, P.K.; Haneuse, S.; Li, G.; Schellenberg, G.D.; Craft, S.; Leverenz, J.B.; Montine, T.J. Pathological correlates of dementia in a longitudinal, populationbased sample of aging. Ann. Neurol., 2007, 62(4), 406-413.
109. Schneider, J.A.; Aggarwal, N.T.; Barnes, L.; Boyle, P.; Bennett, D.A. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J. Alzheimers Dis., 2009, 18(3), 691-701.
110. Petrovitch, H.; Ross, G.W.; Steinhorn, S.C.; Abbott, R.D.; Markesbery, W.; Davis, D.; Nelson, J.; Hardman, J.; Masaki, K.; Vogt, M.R.; Launer, L.; White, L.R. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann. Neurol., 2005, 57(1), 98-103.
111. Barker, W.W.; Luis, C.A.; Kashuba, A.; Luis, M.; Harwood, D.G.; Loewenstein, D.; Waters, C.; Jimison, P.; Shepherd, E.; Sevush, S.; Graff-Radford, N.; Newland, D.; Todd, M.; Miller, B.; Gold, M.; Heilman, K.; Doty, L.; Goodman, I.; Robinson, B.; Pearl, G.; Dickson, D.; Duara, R. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis. Assoc. Disord., 2002, 16(4), 203-212.